Conversely, oncogenic fusions were associated with high and low T cell-inflamed scores, often consistent with PD-L1 IHC status (Figure 4A) indicating that fusions themselves may not reliably predict response to immunotherapy for melanoma. This evidence concerns the gene CD274 and melanoma.